Evidence map›Paper›PMID 27194690›Full record

ArticleJournal of clinical microbiology2016

Multicenter Evaluation of Meridian Bioscience HSV 1&2 Molecular Assay for Detection of Herpes Simplex Virus 1 and 2 from Clinical Cutaneous and Mucocutaneous Specimens.

Matthew L Faron, Nathan A Ledeboer, Anami Patel, Safedin H Beqa, Belinda Yen-Lieberman, Debra Kohn, Amy L Leber, Donna Mayne, William I Northern, Blake W Buchan

Open access · bronzeAbstract readEvaluation Study
In one paragraph

Article in Journal of clinical microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Current and Future Trends in the Laboratory Diagnosis of Sexually Transmitted Infections.International journal of environmental research and public health · 2021
    Review
  3. Amplification chemistries in clinical virology.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2019
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Matthew L FaronMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Nathan A LedeboerMedical College of Wisconsin, Milwaukee, Wisconsin, USA Wisconsin Diagnostic Laboratories, Milwaukee, Wisconsin, USA.
Anami PatelLeBonheur Children's Hospital, Memphis, Tennessee, USA.
Safedin H BeqaPathology, Inc., Torrance, California, USA.
Belinda Yen-LiebermanCleveland Clinic, Cleveland, Ohio, USA.
Debra KohnCleveland Clinic, Cleveland, Ohio, USA.
Amy L LeberNationwide Children's Hospital, Columbus, Ohio, USA.
Donna MayneSacred Heart Hospital, Pensacola, Florida, USA.
William I NorthernCompuNet Clinical Laboratories, Moraine, Ohio, USA.
Blake W BuchanMedical College of Wisconsin, Milwaukee, Wisconsin, USA Wisconsin Diagnostic Laboratories, Milwaukee, Wisconsin, USA bbuchan@mcw.edu.ORCID 0000-0002-4111-048X
Medical College of Wisconsin · USCleveland Clinic · USLe Bonheur Children's Hospital · USNationwide Children's Hospital · USSacred Heart Hospital · USTorrance Memorial Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herpes simplex virus (HSV) causes acute and relapsing symptoms characterized by ulcerative lesions. Laboratory diagnosis of HSV in cutaneous or mucocutaneous lesions has historically been performed with the use of viral cell culture systems; however, these tests are laborious and suffer decreased sensitivity for advanced-stage lesions. The recent availability of FDA-cleared moderately complex assays has resulted in the increased use of molecular diagnostics for the routine detection of HSV in superficial swab specimens. We performed a clinical evaluation of the recently FDA-cleared illumigene HSV 1&2 loop-mediated isothermal amplification (LAMP) assay (Meridian Bioscience, Cincinnati OH) for the detection and differentiation of HSV-1 and HSV-2 in cutaneous and mucocutaneous swab specimens. A total of 1,153 clinical swab specimens were collected and tested at 7 different clinical centers. Each specimen was tested for the presence of HSV-1 and HSV-2 using the illumigene assay, and results were compared to those of the enzyme-linked virus-inducible system (ELVIS) as the reference method. Overall, the illumigene assay demonstrated a sensitivity and specificity of 94.8% and 95.5%, respectively, for the detection of HSV-1. Detection of HSV-2 was similar, with a sensitivity of 98.9% and a specificity of 95.5%. Discrepant analysis was performed using an alternative molecular test (AmpliVue HSV1+2 assay; Quidel Molecular, San Diego, CA) on 91/99 specimens that were recorded as false positive (FP) or false negative (FN) compared to the reference method. In total, 57/78 (73%) FP and 9/13 (69%) FN illumigene results were supported by the AmpliVue result. The illumigene HSV 1&2 assay demonstrated high sensitivity and specificity to detect and differentiate HSV in clinical specimens and identified 57 additional specimens that were positive for HSV compared to culture. The use of LAMP eliminates the need for the cycling of temperatures and provides results in less than 60 min, with approximately 2 min of hands-on time per specimen.

Indexed as

AdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleHerpes GenitalisHerpes SimplexHerpesvirus 1, HumanHerpesvirus 2, HumanHumansInfantInfant, NewbornMaleMiddle Aged

Identifiers

PMID27194690
PMCPMC4963491
OpenAlexW2408289182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.